{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:36:52Z","timestamp":1775151412335,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.jcv.2004.09.030","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T03:07:50Z","timestamp":1103166470000},"page":"110-115","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence and factors involved in discordant responses to highly active antiretroviral treatment in a closely followed cohort of treatment-na\u00efve HIV-infected patients"],"prefix":"10.1016","volume":"33","author":[{"given":"Sonia","family":"Molina-Pinelo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Soriano-Sarabia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ger\u00f3nimo","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M \u00c1ngeles","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Lissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2004.09.030_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2214\/ajr.149.2.269","article-title":"Thymic atrophy and regrowth in response to chemotherapy: CT evaluation","volume":"149","author":"Choyke","year":"1987","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jcv.2004.09.030_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/135965350200700304","article-title":"Baseline thymic volume is a predictor for CD4+ T-cell repopulation in adult HIV-infected patients under highly active antiretroviral therapy","volume":"7","author":"De la Rosa","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2004.09.030_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jmv.2023","article-title":"Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations","volume":"65","author":"Devereux","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcv.2004.09.030_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/25374","article-title":"Changes in thymic function with age and during treatment of HIV infection","volume":"396","author":"Douek","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2004.09.030_bib5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1086\/342695","article-title":"Long-term outcomes among antiretroviral-na\u00efve human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression","volume":"35","author":"Dronda","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.030_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2249.2000.01152.x","article-title":"CD4+ and CD8+ T-lymphocytes regeneration after antiretroviral therapy in HIV-1 infected children and adult patients","volume":"119","author":"Franco","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcv.2004.09.030_bib7","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood.V99.10.3702","article-title":"T cell repopulation and thymic volume in HIV-1-infected patients after highly active antiretroviral therapy","volume":"99","author":"Franco","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcv.2004.09.030_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-133-6-200009190-00007","article-title":"Clinical outcome of patients with infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy","volume":"133","author":"Grabar","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcv.2004.09.030_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00002030-200206140-00013","article-title":"Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss","volume":"16","author":"Hazenberg","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.030_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1074-7613(00)80379-9","article-title":"T cell turnover in HIV-1 disease","volume":"7","author":"Hellerstein","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jcv.2004.09.030_bib11","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1128\/JVI.72.8.6279-6282.1998","article-title":"Role of the Fas\/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease","volume":"72","author":"Kaplan","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2004.09.030_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(98)24010-4","article-title":"CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study","volume":"351","author":"Kaufmann","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2004.09.030_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1310\/F45L-FDKK-Y48N-N2BT","article-title":"Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure","volume":"2","author":"Kravcik","year":"2001","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2004.09.030_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1086\/319285","article-title":"Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virological treatment failure: role of changes in thymic output and T cell death","volume":"183","author":"Lecossier","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.030_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study","volume":"353","author":"Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2004.09.030_bib16","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1172\/JCI8647","article-title":"Factors influencing T-cell turnover in HIV-1-seropositive patients","volume":"105","author":"McCune","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcv.2004.09.030_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1086\/313520","article-title":"Clinical and immunologic response without decrease in viral load in patients with AIDS after 24 months of highly active antiretroviral therapy","volume":"29","author":"Mezzaroma","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.030_bib18","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.279.12.930","article-title":"A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial, Italy, The Netherlands, Canada and Australia Study","volume":"279","author":"Montaner","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jcv.2004.09.030_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nm0298-208","article-title":"Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation","volume":"4","author":"Pakker","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jcv.2004.09.030_bib20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbility and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2004.09.030_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00002030-199807000-00011","article-title":"Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease","volume":"12","author":"Piketty","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.030_bib22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1086\/319861","article-title":"Long-term clinical outcome of human immunodeficiency virus-infected patients with a discordant immunologic and virologic responses to a protease inhibitor-containing regimen","volume":"183","author":"Piketty","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.030_bib23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/00002030-200107060-00018","article-title":"Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex vivo rates of apoptosis","volume":"15","author":"Pitrak","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.030_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00002030-199904160-00007","article-title":"Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen","volume":"13","author":"Renaud","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.030_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/135965350300800404","article-title":"Comparison of thymic function related markers to predict early CD4+ T-cell repopulation in adult HIV-infected patients on HAART","volume":"8","author":"Ruiz-Mateos","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2004.09.030_bib26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V94.3.1021.415k29_1021_1027","article-title":"Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4+ T cells and decreases their susceptibility to apoptosis in vitro and in vivo","volume":"94","author":"Sloand","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jcv.2004.09.030_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/89090","article-title":"Impaired replication of protease inhibitor-resistant HIV-1 in human thymus","volume":"7","author":"Stoddart","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jcv.2004.09.030_bib28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1086\/368359","article-title":"Prolonged CD4+\/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control","volume":"187","author":"Sufka","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.030_bib29","doi-asserted-by":"crossref","unstructured":"The EACS euroguidelines group. European guidelines for the clinical management and treatment of HIV-1-infected adults in Europe. AIDS 2003; 17:S3\u2013S26.","DOI":"10.1097\/00002030-200306002-00002"},{"key":"10.1016\/j.jcv.2004.09.030_bib30","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1097\/00002030-200009080-00011","article-title":"Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy","volume":"14","author":"Wood","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.030_bib31","first-page":"159","article-title":"Discordant increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy","volume":"30","author":"Wood","year":"2002","journal-title":"J AIDS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653204002872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653204002872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T22:51:55Z","timestamp":1682895115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653204002872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1386653204002872"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2004.09.030","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}